Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? [electronic resource]
Producer: 20140122Description: 833-8 p. digitalISSN:- 1525-1438
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Carboplatin -- administration & dosage
- Cisplatin -- administration & dosage
- Cyclophosphamide -- administration & dosage
- Disease Progression
- Docetaxel
- Drug Resistance, Neoplasm -- drug effects
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- administration & dosage
- Prognosis
- Retrospective Studies
- Survival Rate
- Taxoids -- administration & dosage
- Topotecan -- administration & dosage
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.